Palmar-Plantar Erythrodysesthesia Associated with Chemotherapy and Its Treatment
Open Access
- 1 April 2011
- journal article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 4 (1) , 229-235
Abstract
Palmar-plantar erythrodysesthesia (PPE), also called hand-foot syndrome, is a relatively common dermatologic toxic reaction associated with cytotoxic chemotherapy that can limit the use of such drugs. Definitive prevention and treatment strategies for PPE have not yet been established. We present a patient with recurrent ovarian cancer developing severe hand-foot syndrome after treatment with pegylated liposomal doxorubicin. A review of the relevant literature concerning pathophysiology, preventive measures and management of PPE is given. Electronic search was conducted using the Medline database for English-language records. The search terms used were ‘palmar-plantar erythrodysesthesia’, ‘hand-foot syndrome’, ‘pegylated liposomal doxorubicin’ and ‘acral erythema’.Keywords
This publication has 13 references indexed in Scilit:
- Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancerGynecologic Oncology, 2009
- Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective studySupportive Care in Cancer, 2007
- Palmar–plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centreEuropean Journal of Oncology Nursing, 2007
- Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome)Annals of Oncology, 2007
- Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?Annals of Oncology, 2005
- Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancerBiochimica et Biophysica Acta (BBA) - Biomembranes, 2004
- Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancerAnnals of Oncology, 2004
- Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade gliomaCancer, 2004
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapyCancer, 1995